Friday, March 10, 2023 7:10:37 AM
Source: GlobeNewswire Inc.
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, has received clearance by the United States Food and Drug Administration (“FDA”) following review of its Investigational New Drug Application (“IND”) to proceed for clinical testing of its novel MT-8421 ETB program targeting CTLA-4 in patients with relapsed/refractory solid tumors previously exposed to checkpoint inhibitors.
“MT-8421 represents a novel approach to target CTLA-4 in a wholly distinct manner from the current monoclonal antibody approaches. MT-8421 was designed to eliminate CTLA-4-expressing Tregs in the tumor microenvironment (“TME”) through a direct cell-kill mechanism independent of the effector cell presence that antibodies rely upon while not effecting Tregs in the periphery, the major mechanism of antibody-mediated autoimmune toxicity,” said Eric Poma, Chief Executive Officer and Chief Scientific Officer of MTEM.
Preclinical data from MT-8421 showed that in a transgenic mouse model expressing human CTLA-4 and bearing syngeneic subcutaneous tumors, MT-8421 treatment depleted immune suppressive Tregs in the TME but not in the periphery. MT-8421 was well tolerated in a non-human GLP primate toxicology study and achieved serum levels well-above projected IC50 concentrations for Tregs in the TME. MTEM expects to initiate a first-in-human phase I study with MT-8421 by mid-year 2023 at a starting dose of 32 mcg/kg.
About Molecular Templates
Molecular Templates is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. Our proprietary drug platform technology, known as engineered toxin bodies, or ETBs, leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Molecular Templates disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Molecular Templates may identify forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the safety or potential efficacy of Molecular Templates’ drug or biologic candidates; the prospects of CTLA-4 targeting therapies as a potential treatment; statements relating to the development of MT-8421; the expected timing of initiating and completing enrollment of cohorts and conducting the planned Phase I study of MT-8421; and Molecular Templates’ belief that its proprietary biologic drug platform technology, or ETBs, provides for a differentiated mechanism of action for cancer.
Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to, the uncertainties inherent in the preclinical and clinical development process, including the fact that interim results may not be indicative of future results; whether Molecular Templates’ cash resources, will be sufficient to fund its continuing operations for the periods and/or trials anticipated; Molecular Templates’ ability to timely enroll patients in its clinical trials; the ability of Molecular Templates’ to protect its intellectual property rights; risks from global pandemics including COVID-19; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in Molecular Templates’ filings with the SEC. There can be no assurance that any of Molecular Templates’ drug or biologic candidates will be successfully developed, manufactured, or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Any forward-looking statements contained in this press release speak only as of the date hereof, and Molecular Templates specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.
Contacts:
Dr. Grace Kim
Head of Investor Relations
grace.kim@mtem.com
Primary Logo
Recent MTEM News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/17/2024 09:05:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2024 08:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 08:02:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/30/2024 09:41:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/30/2024 09:37:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/30/2024 09:36:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/30/2024 09:36:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/30/2024 09:35:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 08:01:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:36:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:26:10 PM
- Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update • GlobeNewswire Inc. • 08/14/2024 08:21:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/13/2024 08:47:53 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/13/2024 08:44:56 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/13/2024 08:43:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:13:13 PM
- Molecular Templates, Inc. Provides Interim Update • GlobeNewswire Inc. • 06/03/2024 12:11:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:21:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 09:18:03 PM
- Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update • GlobeNewswire Inc. • 05/15/2024 09:11:54 PM
- Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patien • GlobeNewswire Inc. • 04/09/2024 12:11:00 PM
- Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 03/29/2024 12:21:08 PM
- Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement • GlobeNewswire Inc. • 03/28/2024 12:11:00 PM
- Molecular Templates, Inc. Provides Interim Update • GlobeNewswire Inc. • 03/04/2024 01:11:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/15/2024 01:39:50 AM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM